Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about 30% year to date and about 25% over the past 12 months.FinanceCharts

NYSE:LLY
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock.
9 December 2025
······
Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November on the back of explosive demand for its obesity and diabetes drugs, the stock has pulled back slightly but remains near record highs. Reuters+1
6 December 2025
···
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly and Company has just wrapped up one of the most dramatic months in its history. The drugmaker’s shares have surged in November, pushing the company past a $1 trillion market value and cementing its role as the stock market’s flagship obesity‑drug play. At the same time, fresh commentary this weekend is increasingly focused on one question: is Lilly’s stock now priced for perfection?
30 November 2025
··
Eli Lilly (LLY) Stock Outlook Before Market Open on November 28, 2025: Trillion‑Dollar Pharma in Focus

Eli Lilly (LLY) Stock Outlook Before Market Open on November 28, 2025: Trillion‑Dollar Pharma in Focus

As U.S. markets prepare for a shortened Black Friday session on Friday, November 28, 2025, Eli Lilly and Company will open trading as one of the most closely watched stocks on Wall Street. The drugmaker has just joined the exclusive $1 trillion market‑cap club thanks to explosive demand for its GLP‑1 weight‑loss and diabetes drugs, alongside new momentum in Alzheimer’s disease and oncology.
27 November 2025
·
Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

Stock Market Today, November 26, 2025: Dow Futures Rise On Fed Rate-Cut Bets As Nvidia, Apple, Bitcoin And Eli Lilly Take Center Stage

U.S. stock futures are pointing higher on the Wednesday before Thanksgiving as Wall Street rides a three-day winning streak and bets that the Federal Reserve will cut interest rates in December. At the same time, some of the market’s biggest story stocks — Nvidia, Apple, Bitcoin-linked names and Eli Lilly — are moving on fresh headlines that could shape trading into year‑end. Reuters+2Nasdaq+2
26 November 2025
·····
Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly and Company remains one of the most closely watched stocks on Wall Street today as it trades just below the historic $1 trillion valuation it briefly reached on Friday, while fresh analyst upgrades, new obesity‑drug data and a major setback for rival Novo Nordisk’s Alzheimer’s program dominate the news cycle. Reuters+1
24 November 2025
·
1 … 9 10 11 12 13 14
Follow on Google News
Add as preferred source Open in Google News